NorthRock Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $476K | Buy |
8,260
+984
| +14% | +$56.5K | 0.01% | 451 |
|
|
2026
Q1 | $441K | Buy |
7,276
+968
| +15% | +$56.4K | 0.01% | 432 |
|
|
2025
Q4 | $340K | Sell |
6,308
-26,594
| -81% | -$1.28M | 0.01% | 448 |
|
|
2025
Q3 | $1.48M | Buy |
32,902
+5,226
| +19% | +$244K | 0.03% | 259 |
|
|
2025
Q2 | $1.28M | Sell |
27,676
-1,059
| -4% | -$52K | 0.03% | 199 |
|
|
2025
Q1 | $1.75M | Buy |
28,735
+1,976
| +7% | +$115K | 0.06% | 132 |
|
|
2024
Q4 | $1.51M | Buy |
26,759
+594
| +2% | +$33.2K | 0.05% | 146 |
|
|
2024
Q3 | $1.35M | Buy |
26,165
+9,142
| +54% | +$429K | 0.04% | 175 |
|
|
2024
Q2 | $707K | Buy |
17,023
+1,486
| +10% | +$66.5K | 0.03% | 257 |
|
|
2024
Q1 | $843K | Buy |
15,537
+1,250
| +9% | +$63.7K | 0.03% | 230 |
|
|
2023
Q4 | $733K | Buy |
14,287
+3,781
| +36% | +$198K | 0.03% | 234 |
|
|
2023
Q3 | $610K | Buy |
10,506
+624
| +6% | +$38.2K | 0.06% | 129 |
|
|
2023
Q2 | $632K | Buy |
9,882
+664
| +7% | +$44.5K | 0.07% | 112 |
|
|
2023
Q1 | $639K | Sell |
9,218
-2,360
| -20% | -$166K | 0.07% | 125 |
|
|
2022
Q4 | $833K | Buy |
11,578
+3,459
| +43% | +$261K | 0.09% | 110 |
|
|
2022
Q3 | $577K | Sell |
8,119
-1,045
| -11% | -$75.8K | 0.07% | 131 |
|
|
2022
Q2 | $706K | Sell |
9,164
-223
| -2% | -$17K | 0.07% | 120 |
|
|
2022
Q1 | $686K | Buy |
9,387
+2,379
| +34% | +$160K | 0.06% | 141 |
|
|
2021
Q4 | $437K | Buy |
7,008
+1,460
| +26% | +$85.6K | 0.03% | 192 |
|
|
2021
Q3 | $328K | Buy |
5,548
+571
| +11% | +$37.6K | 0.03% | 200 |
|
|
2021
Q2 | $333K | Buy |
4,977
+251
| +5% | +$16.4K | 0.03% | 184 |
|
|
2021
Q1 | $298K | Sell |
4,726
-1,604
| -25% | -$99.8K | 0.03% | 176 |
|
|
2020
Q4 | $393K | Sell |
6,330
-981
| -13% | -$60.3K | 0.04% | 147 |
|
|
2020
Q3 | $441K | Sell |
7,311
-1,056
| -13% | -$63.6K | 0.05% | 131 |
|
|
2020
Q2 | $492K | Buy |
8,367
+414
| +5% | +$24.8K | 0.06% | 118 |
|
|
2020
Q1 | $443K | Sell |
7,953
-6,052
| -43% | -$370K | 0.06% | 118 |
|
|
2019
Q4 | $899K | Buy |
14,005
+8,750
| +167% | +$501K | 0.1% | 107 |
|
|
2019
Q3 | $266K | Buy |
+5,255
| New | +$247K | 0.04% | 181 |
|
|
2019
Q1 | – | Sell |
-4,480
| Closed | -$232K | – | 96 |
|
|
2018
Q4 | $232K | Buy |
+4,480
| New | +$241K | 0.07% | 82 |
|
Other funds holding BMY
NorthRock Partners's BMY Position: Q2 2026 in Review
NorthRock Partners increased its Bristol-Myers Squibb (BMY) stake by 14% in Q2 2026, buying an estimated $56.5K and bringing the position to 8,260 shares worth $476K. The position accounts for 0.01% of the portfolio, ranked #451.
NorthRock Partners first reported a position in BMY in Q4 2018 and has held it in 29 quarters since. The position peaked at $1.75M in Q1 2025. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- NorthRock Partners held 8,260 shares of Bristol-Myers Squibb worth $476K as of Q2 2026.
- NorthRock Partners bought 984 Bristol-Myers Squibb shares in Q2 2026, an estimated $56.5K.
- Bristol-Myers Squibb made up 0.01% of NorthRock Partners's portfolio in Q2 2026, its #451 holding.
- NorthRock Partners first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 29 quarters since.
- NorthRock Partners's Bristol-Myers Squibb position peaked at $1.75M in Q1 2025.
- 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on NorthRock Partners's 13F filing for Q2 2026, filed 11 Aug 2026.